CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for?multiple myeloma.?
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy for Multiple Myeloma. This report contains market size and forecasts of CAR T-Cell Therapy for Multiple Myeloma in global, including the following market information:
Global CAR T-Cell Therapy for Multiple Myeloma Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global CAR T-Cell Therapy for Multiple Myeloma market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area. Car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CAR T-Cell Therapy for Multiple Myeloma companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR T-Cell Therapy for Multiple Myeloma Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global CAR T-Cell Therapy for Multiple Myeloma Market Segment Percentages, by Type, 2022 (%)
Monotherapy
Combination Therapy
Global CAR T-Cell Therapy for Multiple Myeloma Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global CAR T-Cell Therapy for Multiple Myeloma Market Segment Percentages, by Application, 2022 (%)
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
Global CAR T-Cell Therapy for Multiple Myeloma Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global CAR T-Cell Therapy for Multiple Myeloma Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CAR T-Cell Therapy for Multiple Myeloma revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies CAR T-Cell Therapy for Multiple Myeloma revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Outline of Major Chapters:
Chapter 1: Introduces the definition of CAR T-Cell Therapy for Multiple Myeloma, market overview.
Chapter 2: Global CAR T-Cell Therapy for Multiple Myeloma market size in revenue.
Chapter 3: Detailed analysis of CAR T-Cell Therapy for Multiple Myeloma company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CAR T-Cell Therapy for Multiple Myeloma in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 CAR T-Cell Therapy for Multiple Myeloma Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CAR T-Cell Therapy for Multiple Myeloma Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CAR T-Cell Therapy for Multiple Myeloma Overall Market Size
2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size: 2022 VS 2032
2.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CAR T-Cell Therapy for Multiple Myeloma Players in Global Market
3.2 Top Global CAR T-Cell Therapy for Multiple Myeloma Companies Ranked by Revenue
3.3 Global CAR T-Cell Therapy for Multiple Myeloma Revenue by Companies
3.4 Top 3 and Top 5 CAR T-Cell Therapy for Multiple Myeloma Companies in Global Market, by Revenue in 2022
3.5 Global Companies CAR T-Cell Therapy for Multiple Myeloma Product Type
3.6 Tier 1, Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Players in Global Market
3.6.1 List of Global Tier 1 CAR T-Cell Therapy for Multiple Myeloma Companies
3.6.2 List of Global Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Market Size Markets, 2022 & 2032
4.1.2 Monotherapy
4.1.3 Combination Therapy
4.2 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
4.2.1 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2023
4.2.2 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2024-2032
4.2.3 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Market Size, 2022 & 2032
5.1.2 Multiple Myeloma
5.1.3 Refractory or Relapsed Multiple Myeloma
5.2 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
5.2.1 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2023
5.2.2 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2024-2032
5.2.3 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Market Size, 2022 & 2032
6.2 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
6.2.1 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2023
6.2.2 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2024-2032
6.2.3 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2032
6.3.2 US CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.3.3 Canada CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.3.4 Mexico CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2032
6.4.2 Germany CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.4.3 France CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.4.4 U.K. CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.4.5 Italy CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.4.6 Russia CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.4.7 Nordic Countries CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.4.8 Benelux CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2032
6.5.2 China CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.5.3 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.5.4 South Korea CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.5.5 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.5.6 India CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2032
6.6.2 Brazil CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.6.3 Argentina CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2032
6.7.2 Turkey CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.7.3 Israel CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.7.4 Saudi Arabia CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
6.7.5 UAE CAR T-Cell Therapy for Multiple Myeloma Market Size, 2018-2032
7 CAR T-Cell Therapy for Multiple Myeloma Companies Profiles
7.1 Juno Therapeutics
7.1.1 Juno Therapeutics Company Summary
7.1.2 Juno Therapeutics Business Overview
7.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.1.4 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2018-2023)
7.1.5 Juno Therapeutics Key News & Latest Developments
7.2 Kite Pharma
7.2.1 Kite Pharma Company Summary
7.2.2 Kite Pharma Business Overview
7.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.2.4 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2018-2023)
7.2.5 Kite Pharma Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.3.4 Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Collectis
7.4.1 Collectis Company Summary
7.4.2 Collectis Business Overview
7.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.4.4 Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2018-2023)
7.4.5 Collectis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. CAR T-Cell Therapy for Multiple Myeloma Market Opportunities & Trends in Global Market
Table 2. CAR T-Cell Therapy for Multiple Myeloma Market Drivers in Global Market
Table 3. CAR T-Cell Therapy for Multiple Myeloma Market Restraints in Global Market
Table 4. Key Players of CAR T-Cell Therapy for Multiple Myeloma in Global Market
Table 5. Top CAR T-Cell Therapy for Multiple Myeloma Players in Global Market, Ranking by Revenue (2022)
Table 6. Global CAR T-Cell Therapy for Multiple Myeloma Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Companies, 2018-2023
Table 8. Global Companies CAR T-Cell Therapy for Multiple Myeloma Product Type
Table 9. List of Global Tier 1 CAR T-Cell Therapy for Multiple Myeloma Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2024-2032
Table 30. Juno Therapeutics Company Summary
Table 31. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 32. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2018-2023)
Table 33. Juno Therapeutics Key News & Latest Developments
Table 34. Kite Pharma Company Summary
Table 35. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 36. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2018-2023)
Table 37. Kite Pharma Key News & Latest Developments
Table 38. Novartis Company Summary
Table 39. Novartis CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 40. Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2018-2023)
Table 41. Novartis Key News & Latest Developments
Table 42. Collectis Company Summary
Table 43. Collectis CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 44. Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2018-2023)
Table 45. Collectis Key News & Latest Developments
List of Figures
Figure 1. CAR T-Cell Therapy for Multiple Myeloma Segment by Type in 2022
Figure 2. CAR T-Cell Therapy for Multiple Myeloma Segment by Application in 2022
Figure 3. Global CAR T-Cell Therapy for Multiple Myeloma Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global CAR T-Cell Therapy for Multiple Myeloma Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2022
Figure 8. By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 9. By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 10. By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 12. By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 14. By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 15. By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 16. US CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 17. Canada CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 20. Germany CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 21. France CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 23. Italy CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 24. Russia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 28. China CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 29. Japan CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 32. India CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 34. Brazil CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2018-2032
Figure 37. Turkey CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 38. Israel CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 40. UAE CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2018-2032
Figure 41. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
